Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
| Autor: | Giovanni Francesco Pellicanò, Giuliano Rizzardini, A. Di Biagio, M. Franzetti, Patrizia Zucchi, Adriana Ammassari, Elena Mazzotta, Simona Landonio, Gaetana Sterrantino, S Lo Caputo, G. V. De Socio, Paola Meraviglia, Amedeo Capetti, Barbara Menzaghi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Pediatrics
medicine.medical_specialty Pathology business.industry Public health education Public Health Environmental and Occupational Health Integrase inhibitor Salvage therapy Raltegravir medicine.disease Regimen Infectious Diseases Pharmacotherapy Acquired immunodeficiency syndrome (AIDS) Expanded access Poster Presentation medicine business health care economics and organizations medicine.drug |
| Zdroj: | Journal of the International AIDS Society |
| ISSN: | 1758-2652 |
| Popis: | Raltegravir is the first integrase inhibitor to get into the clinic and the MK-0518 Expanded Access Program (EAP) started in Italy in 2007, so that most patients now have an observation period of two years. Up to date a few studies have described the durability of raltegravir-containing regimen with a follow up of 96 weeks. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P38 Cite this article as: Landonio et al.: Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience. Journal of the International AIDS Society 2010 13(Suppl 4):P38. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113040/ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink